Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

Université Laval

$25,000.00

Quantitative biodistribution of viral nanoparticles by nuclear imaging

FY 2017-18

Summary
Virus-Like Particles (VLPs) represent one of the most exciting emerging vaccine technologies for generatingeffective and long-lasting immune protection. VLPs consist of protein shells studded with short strands of theproteins specific to whatever disease the vaccine is intended to control. VLPs are made to look like a virus,allowing them to be recognized readily by the body's immune system, however, they lack the core geneticmaterial, making them non-infectious and unable to replicate.The development of a reliable and efficient quantitative biodistribution methodology based on nuclear imaging,is a prerequisite for the development of mid and long-term research projects aiming at establishing strongcorrelations between the strength of the immune response, and the local presence of virus-like particles in vivo.This project will enable the development of an efficient methodology a) to radiolabel VLP with radioisotopesfor positron emission tomography (PET), b) to purify thus-radiolabeled VLPs by size-exclusionchromatography (SEC), 3) to provide PET biodistribution of radiolabeled VLPs, injected in a mouse model.This short-term research project will provide the following key information, essential for planning subsequentVLP biodistribution studies: radiolabeling parameters (chelate, chelate binding reaction time, temperature,chelation challenge); SEC purification parameters (max. mass of VLP to be eluted; elution kinetics; elutionprofile; handling of radioactive waste produced by SEC); parameters for preserving VLP functionality;minimum mass and activity of radiolabeled VLP to be injected, to reach acceptable PET biodistributionprofiles. At the end of this short-term project, the company will have access to a complete methodology for thePET biodistribution of VLPs in vivo. The team will be able to plan a full-scale research project, with the aim ofcorrelating the effectiveness of VLPs as vaccination products, with several biodistribution signatures revealedin PET data. This methodology has the potential to accelerate the validation of new VLP-based vaccines.
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
509485-2017
Name nom
Fortin, MarcAndré
Department département
Génie des mines, métallurgie et matériaux
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Quantitative biodistribution of viral nanoparticles by nuclear imaging
Keyword
NSERC
Application summary
Virus-Like Particles (VLPs) represent one of the most exciting emerging vaccine technologies for generatingeffective and long-lasting immune protection. VLPs consist of protein shells studded with short strands of theproteins specific to whatever disease the vaccine is intended to control. VLPs are made to look like a virus,allowing them to be recognized readily by the body's immune system, however, they lack the core geneticmaterial, making them non-infectious and unable to replicate.The development of a reliable and efficient quantitative biodistribution methodology based on nuclear imaging,is a prerequisite for the development of mid and long-term research projects aiming at establishing strongcorrelations between the strength of the immune response, and the local presence of virus-like particles in vivo.This project will enable the development of an efficient methodology a) to radiolabel VLP with radioisotopesfor positron emission tomography (PET), b) to purify thus-radiolabeled VLPs by size-exclusionchromatography (SEC), 3) to provide PET biodistribution of radiolabeled VLPs, injected in a mouse model.This short-term research project will provide the following key information, essential for planning subsequentVLP biodistribution studies: radiolabeling parameters (chelate, chelate binding reaction time, temperature,chelation challenge); SEC purification parameters (max. mass of VLP to be eluted; elution kinetics; elutionprofile; handling of radioactive waste produced by SEC); parameters for preserving VLP functionality;minimum mass and activity of radiolabeled VLP to be injected, to reach acceptable PET biodistributionprofiles. At the end of this short-term project, the company will have access to a complete methodology for thePET biodistribution of VLPs in vivo. The team will be able to plan a full-scale research project, with the aim ofcorrelating the effectiveness of VLPs as vaccination products, with several biodistribution signatures revealedin PET data. This methodology has the potential to accelerate the validation of new VLP-based vaccines.